About TrueGenix
TrueGenix® is a clinically focused regenerative medicine company dedicated to advancing therapeutic solutions through ethically sourced, proprietary biologic technologies. Utilizing human mesenchymal stem cell–derived conditioned media, TrueGenix® develops scientifically engineered treatments designed to support tissue repair, cellular regeneration, and functional restoration.
​
Our patented processes leverage carefully controlled cell expansion and culture protocols to produce high-quality, biologically active conditioned media. This approach enables the delivery of powerful regenerative signaling factors without the use of live cells, ensuring both safety and consistency in clinical application.
​
TrueGenix® therapies are designed to address a range of medical and aesthetic conditions, including skin rejuvenation, acne and scar reduction, neuropathy, and chronic diabetic wounds and burn care. Each formulation is developed with a focus on clinical efficacy, reproducibility, and real-world therapeutic outcomes.
​
Built on decades of scientific research and translational medicine, TrueGenix® represents the convergence of advanced biotechnology and practical clinical application—bringing next-generation regenerative solutions to providers and patients.
TrueGenix® was founded through the partnership of Dr. Jonathan R.T. Lakey, Ph.D., MSM, and William H. Gafford Jr.
​
Dr. Lakey is an internationally recognized expert in biomaterials, stem cells, diabetes, and islet transplantation. He is Professor Emeritus in the Departments of Surgery and Biomedical Engineering at the University of California, Irvine (UCI), where he previously served as Director of Research for the Clinical Islet Program and Stem Cell Laboratory. With over 500 peer-reviewed publications, numerous book chapters, and multiple patents, his work has significantly advanced the global understanding and clinical application of stem cell–derived therapies.
​
William H. Gafford Jr. is a former banking executive and healthcare innovator with extensive experience in scaling medical technologies and building strategic partnerships within the healthcare ecosystem. He brings operational leadership and commercialization expertise to the advancement of regenerative medicine solutions.